Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
HBD. Great post. Maybe I'm not a not a nut job.
Yes WIP Blubell Capital.'not acting in concert with Elliott.
But has the same aims.....
Institutions not happy with GSK. They need a rabbit out of the hat.
Just read Lazarus post re shareholders and board members re best interests. Absolutely agree. But can I turn this on its head given our board members experience at GSK and our ipr that is progressing, recently upgraded and on the back burner due to financial constraints despite promising results and yes some out on licence....yawn, but a little nugget re 737 pipeline.
So DM Financial today re GSK imminent split, we have all read it. There is a hedge fund (Elliot which invested billions in GSK earlier this year) that surprisingly joined a meeting and questioned Walmsleys leadership (ceo of gsk) in front of GSKs chairman and 50 top investors at a private virtual event.
Elliot demanded a process to pick the next boss of new GSK.
However, Banga (GSK Senior independent Director) said management had a few more rounds left in them...Walmsleys lack of scientific experience has been repeatedly questioned as she prepares to lead new GSK.
Elliot worth $40b has committed to bringing in directors with scientific backgrounds. It is understood Symonds expressed frustration in finding suitable executives with no conflicts of interest.
So I put it re above our best interest is a takeover with GSK and they take on our ipr (not sure how pre licenced ipr works but funny how their was news re 737) and also our board with scientific expertise. So conflict of interest removed. That's two birds with one stone for a major global pharma wanting to appease shareholders and institutions.
Final bit
GSK Head of research John Lepore said 'we follow the world's most innovative science to develop transformational medicines for patients'
Just a muse. As I'm sure you all appreciate so many dots and thoughts. That's mine.
Steadydanny
I appreciate I prattle on re GSK. I don't want to waste space here and your time but just read an article which gives me a thought provoking muse.
If it gets 10 tick ups given its a quiet Sunday I will post it. If not I will not waste the space for more informative posts.
Regards Steadydanny
Good shout HBD. Regards Steady.
Just reminds me of when I was a kid nearing xmas and trying to trip mum up via a conversation to find out what I was getting for Xmas.
In fairness if you knew before the big day the surprise was lost, and the magic of that day.
So many muses so many gift options and I'm convinced we aren't going to be fobbed off with socks.
A Bmx was always my biggest wish. But got a secondhand puch girls bike. Nevertheless the wealthier kids who got bmxs still couldn't beat me at wheelies or ramp jumps. oh the heady days of constant scabs on your knees and jumpers for goalposts.
Best of luck all and thanks HBD...here's to a great week ahead.....
Hi HBD. My bringing the lupus discussion last night re lupus and dod was this news release by gsk yesterday
GSK update todaySat 20:54
Blanche, living with #lupus, shares her experience with this complex disease. At #LUPUSCORA21 and beyond, GSK is committed to bringing healthcare professionals together to create a collaborative, long-term treatment approach for lupus.
about 7 hours ago ..today...... now yesterday
As you pointed out the results were very encouraging re lupus but got stalled due to a bizarre visa problem despite our July 2020 rns stating
These studies were supported by a research grant from the US Department of Defense (DoD) and the report was recently published on the website of the Defense Technical Information Center (https://apps.dtic.mil/sti/citations/AD1087498).
The authors concluded that an approach using selective TYK2/JAK1 inhibitors may lead to the development of a therapy for lupus that does not involve the harmful side effects of systemic immune system suppression and may benefit numerous lupus patients in need of new options. They also noted that the results could influence treatments of other autoimmune diseases such as arthritis and psoriasis.
So my thought pattern is the then newly named 1802 like 737 and flt3 (appreciate different) seemed to have got mothballed despite promising results which late Sept this year gsk noted a $300m contract re its vaccines with dod.
What if gsk somehow have been working on that 1802 since last year quietly and have made progress hence yesterday's news from them (above) and our recent 1802 patent upgrade to give us a new angle with 1802.
Just my rambling. Happy to be put right. Appreciate hypothetical.
Regards Steadydanny
Let's dream together. But I'm seeing our news output as being withheld with snippets released as deemed acceptable so as not alert the competition. I used to deal directly with DoD and it wasn't pharma but specialist vehicles. We never saw DoD on the paperwork until trials and retrofits had been approved. It was spin off organisations that acted as deflection from the classified nature. Then the other contracts came in with DoD on them.
I sincerely think we are being held back sp wise. But research goes on imo (experience) even before it is advised it will take place. And before you know it, it is delivered.
Happy here. Appreciate the links.
Best regards Steadydanny
Cheers Thoth. Is this something that might confer the military link?
GlaxoSmithKline LLC, Durham, North Carolina, was awarded a $279,862,800 firm-fixed-price contract for procurement, storage, and distribution of GlaxoSmithKline's monoclonal antibody therapeutic treatment Sotrovimab. Bids were solicited via the internet with one received. Work will be performed in Durham, North Carolina, with an estimated completion date of May 19, 2022. Fiscal 2021 Defense Production Act purchases, defense funds in the amount of $279,862,800 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity (W58P05-21-C-0008). (Awarded Sept. 29, 2021)
Greatly appreciate your thoughts.
Many thanks Steady
Blanche, living with #lupus, shares her experience with this complex disease. At #LUPUSCORA21 and beyond, GSK is committed to bringing healthcare professionals together to create a collaborative, long-term treatment approach for lupus.
about 7 hours ago ..today
Mitchell July 2020
The TYK2/JAK1 inhibitor SAR-20351 (now known as SDC-1802) has been selected as a preclinical development candidate targeting cancer based on its overall profile that includes supportive data recently presented in October 2019 at the AACR-NCI-EORTC International Cancer Conference. Sareum is advancing a different TYK2/JAK1 inhibitor - SDC-1801 - as a preclinical candidate targeting autoimmune diseases.
"These data from studies using our small molecule TYK2/JAK1 inhibitors add to the body of evidence supporting this novel mechanism of action as a promising approach to treating autoimmune diseases such as SLE,” Tim Mitchell, the chief executive officer of Sareum said in a statement.
“Our own studies have also confirmed this potential in autoimmune diseases such as psoriasis and rheumatoid arthritis and we are delighted that this work indicates a possible application in lupus, which remains a condition with high unmet medical need,” he added.
Lupus is an autoimmune disease in which the body's immune system attacks healthy tissue in many parts of the body.
“This approach has also been recognised more broadly in the industry with several molecules targeting this pathway advancing through development. We look forward to reporting further progress as we advance our TYK2/JAK1 candidates through preclinical development,” Mitchell said.
I'm still thinking GSK have something simmering with us. Appreciate they stopped ongoing research with Merck (albeit I believe ovarian cancer) but GSK imo are pretty much running things globally. Not a bad team to be on the right side of.
Can someone hopefully jog my memory re something we had to do with the US military and dates. I'm sure we had something that occurred.
If not please ignore. Just something I've come across. Be nice if some criss correlation.
Mafuta the other UT at GSK? They have delayed their split re requirements for new ipr. Monday looks good in my books. Just a hint
Also just a heads up Pfizer joined up with Akeso HK re ccRcc in August this year. 1802 upgrade is not a whim. The timing is not just a coincidence.
Seriously think we have something here that we will get to hear about soon.
Given our recent RNS I wonder if anyone has a thought on the value that 1802 might have increased by.
This from our website re strategy
ApproachBenefit
Pursue multiple programmes Increase potential success rate Mitigate development risk Seek collaboration partners Spread financial cost and risk Introduce specialist research expertise
Develop programmes to pre-clinical/
early clinical development
Minimise ongoing development risk Move up value chain Potential for higher deal values
So the last bit higher deal values. Not forgetting their approach to which stage they 'tend' to get products. Hence what has the new updated 1802 patent added. They imo are definitely onto something to undertake the patent application.
Also our approach re out licensing...
Out-licensing – We aim to out-license our development programmes to pharmaceutical and biotechnology partners at the preclinical or early clinical stages. Out-license agreements typically consist of an upfront payment, development milestone payments and sales royalties. In-licensing – To maintain our product pipeline we continue to investigate sources of new research opportunities.
So putting it out their re what was in the RNS yesterday re key territories (sure we have it printed on our minds so won't copy that) and given upfront payment, milestone payments ( which I believe we are drawing up the trial plan for whoever/or us, we have a bit of leverage financially to not get seen as desperate) and royalties, what figures do people think.
Disclaimer
No other ipr products in the sareum library should feel under appreciated as we have faith in you.
Best regards Steadydanny
And this from Alliance News 19th August re Tim Mitchell
Research project SDC-1801 for treating symptoms of Covid-19 completes, but for treating autoimmune diseases delayed. Cancer immunotherapy project SDC-1802 is ongoing. "We are particularly pleased to have raised substantial additional funding during the period, which will be deployed to advance these programmes into clinical development and build a robust data package to support our ongoing partnering activities for these exciting and differentiated assets," said Chief Executive Tim Mitchell.
Build a robust data package....sar imo are definitely in discussions and are in discussions with noteable potential licensees. They are providing the roadway for trial advancement. Its almost like a set of rules to potential licensees. Our way or flip off. Love it. We are definitely in the driving seat.
I'm really rather excited.
From the RNS today
Sareum's CSO, Dr John Reader, commented:
"We are pleased to confirm the grant of this US patent for SDC-1802, adding another layer of protection around this promising candidate in key territories. Our SDC-1802 programme is in preclinical development currently and we are designing the translational studies needed to define the optimal cancer application prior to completing toxicology and manufacturing studies. We look forward to providing further updates on progress as we achieve key milestones."
So I take from that that we are putting a turnkey plan re 1802 for an incoming license agreement purchaser/s. As in what we recommend for a licensee to get on board with a methodical plan of future trials. As per our website we get products to a certain level...
Out-licensing – We aim to out-license our development programmes to pharmaceutical and biotechnology partners at the preclinical or early clinical stages. Out-license agreements typically consist of an upfront payment, development milestone payments and sales royalties.
But on the other hand we do stipulate that we could also do it in-house.
So I'm thinking given the pharma world know we have a healthy bank account with new subscriptions we are not going to let it go cheap as we hold a great hand of cards. I think the board are playing an absolute blinder here.
So this all looks very nice to me.
Steadydanny
Wip the bill and melinda gates put money into it some 20 years or so ago! I think it is called PATH. So much going on.
Hi Mafuta I believe may 2020 rns
I believe we discussed similar back along...it was a heady and exciting conversation
Specifically, it was reported that treatment with TYK2/JAK1 inhibitor SAR-20351 (now known as SDC-1802) reduces autoantibodies (biological markers of lupus severity) in a spontaneous mouse model of SLE. The data also provided evidence that SAR-20351 inhibits cytokines that play a critical role in lupus, including interferon-alpha, IL-6 and IL-23. The inhibition of IL-23 signalling by SAR-20351 may play a role in the decrease of autoantibodies in the lupus mouse model, as IL-23 signalling drives the differentiation of Th17 cells, which leads to autoantibody production and are pathogenic in lupus.
Then this re malaria vaccine
Hyperparasitemia was associated with significantly lower levels of IL-6 (336.6 versus 602.1; P = 0.002). These results illustrate the complex relationships between inflammatory cytokines and disease in P. falciparum malaria.
Just Google il6 and malaria.
Getting very interesting
The reason I mention GSK malaria vaccine is our links. Harry Finch and Michael Owen involvement at GSK. Its on our management page. Both highly regarded with numerous patents. And on another point the change in broker as pointed out earlier is noteable re FDA involvement.
What if we are part of the malaria vaccine that was rolled out in 2019 but goes back 30 years with GSK and I believe will only take a 5% cut. One of our advisors had 24 years at GSK.
What if 'healing the world' has a different avenue?
Just a muse. Scroll past.
But you don't leave GSK unless you are onto something with your own knowledge and experience and would like a bigger slice of the cake elsewhere that isn't lost in big pharma.
Definitely interesting here.
Re my thoughts on them needing ipr I was watching their sp and volume and it went haywire. The spread had minus 29%. I think I saw buys suddenly jump £30m. Am I right they have something to do with a malaria vaccine. Just approved by WHO.
If so they are in a strong buying position. Definitely help the split. Thoughts appreciated.
Definitely selling going on again at GSK. They need some good news on tie ups with companies with promising pipelines given their imminent split up.
Are we going to see New GSK in a RNS here at some point?